Barclays’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JHC
Barclays's RLMD Position: Q3 2026 in Review
Barclays reduced its Relmada Therapeutics (RLMD) stake by 22% in Q3 2026, selling an estimated $56.1K and leaving 39,798 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.
Barclays first reported a position in RLMD in Q1 2022 and has held it in 18 quarters since. The position peaked at $679K in Q1 2024. 133 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.
- Barclays held 39,798 shares of Relmada Therapeutics worth $150K as of Q3 2026.
- Barclays sold 11,436 Relmada Therapeutics shares in Q3 2026, an estimated $56.1K.
- Relmada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4129 holding.
- Barclays first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 18 quarters since.
- Barclays's Relmada Therapeutics position peaked at $679K in Q1 2024.
- 133 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.